Rapidly climbing sales of the new obesity drug Zepbound and its counterpart for diabetes, Mounjaro, pushed Eli Lilly to a better-than-expected first-quarter profit.
The drugmaker also hiked its sales and earnings forecast for 2024 beyond Wall Street’s expectations even as it hustles to boost manufacturing and catch up to surging demand for the drugs.
Lilly said it was still dealing with supply issues that also hampered the company in the fourth quarter. Company officials expect that to persist through this year, but they emphasized Tuesday that help was on the way.
They expect significant manufacturing increases to occur, starting in the back half of the year.
CEO David Ricks told analysts Tuesday that Lilly was undergoing “the most ambitious expansion plan in our company’s history.”
Indianapolis-based Eli Lilly and Co. recorded $517 million in sales from Zepbound, which received approval from U.S. regulators last November. Total Mounjaro sales more than tripled to $1.81 billion from $568 million in last year’s quarter.
ACL injuries are more common in women soccer players than men. We may learn why
Shanghai to Athens airline route set to launch in April
20th Shambhala Tourism Festival kicks off in Gansu
Stock market mulls future as IPOs slow
EPA rule bans toxic chemical methylene chloride, toxic solvent known to cause liver cancer
Intangible cultural heritages from east China to adorn lunar new year celebration in Sydney
Shenzhen to enhance foreigners' e
Pic story of shadow play artist in Shaanxi
India recalls Rishabh Pant for T20 World Cup after near
AI crucial to NEV supremacy, agree auto execs
The cancer drugs that could improve survival rates if given to patients in the morning
All eyes on Xiaomi car to see if it can trump rivals